<DOC>
	<DOC>NCT00302991</DOC>
	<brief_summary>Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.</brief_summary>
	<brief_title>Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months Symptomatic epilepsy due to malignant brain tumour or progressive brain disease. Confirmed diagnosis of a concomitant chronic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Observational</keyword>
	<keyword>cross-sectional</keyword>
	<keyword>health-related quality of life</keyword>
	<keyword>adverse effects</keyword>
	<keyword>Baker´s AEP scale validation</keyword>
	<keyword>epilepsy</keyword>
</DOC>